Skin ConditionNCT07605871
Effects of Oral Collagen Drinks on Human Skin
A study testing Collagen Drink, MAXI Collagen Drink and MAXI Collagen Drink_High dose in people with Skin Condition and Collagen Synthesis, run by TCI Co., Ltd. at 1 site in China.
Trial summary
The objective of this study is to evaluate the effect of oral collagen drink and MAXI collagen drink on human skin condition improvement. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Skin Condition, Collagen Synthesis
- What is being tested?
- Collagen Drink, MAXI Collagen Drink and MAXI Collagen Drink_High dose
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 105 participants
- Where
- 1 siteChina
- Study dates
- 12 May 2026to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy Chinese subjects aged 18 to 60 years, both male and female.
- Wrinkle Severity: Crow's feet graded 2-4; under-eye fine lines graded 2-5; nasolabial folds graded 1-3.
- Presence of facial skin laxity and sagging.
- Ability to undergo skin examinations and pre-treatment in the designated test areas.
- Ability to understand the trial process, participate voluntarily, and sign a written Informed Consent Form (ICF).
Who cannot join
- Pregnant or lactating women, or those planning to become pregnant in the near future.
- Highly sensitive constitution, history of allergic diseases, or history of allergies to cosmetics.
- Presence of skin diseases (e.g., psoriasis, eczema, atopic dermatitis, severe acne) or other chronic systemic diseases.
- Skin conditions in the test area such as birthmarks, hyperpigmentation, inflammation, scars, nevi (moles), or hypertrichosis (excessive hair).
- Use of anti-inflammatory drugs (e.g., oral or topical corticosteroids) within the past month.
- Use of cosmetics or other products with similar efficacy within the past 2 weeks.
- Participation in other human clinical trials for cosmetics within the past month.
- Any other conditions deemed unsuitable for participation based on clinical assessment.
Trial locations and contacts
1 site in 1 country.
About this study
The objective of this study is to evaluate the effect of oral collagen drink and MAXI collagen drink on human skin condition improvement.
Read the detailed description
This study is a single-center, double-blinded, parallel human trial designed to evaluate the skin beauty effect of oral collagen drink and MAXI collagen drink.
Healthy adult participants aged 18-60 years will be enrolled. Participants will be informed to consume test samples daily for 4 consecutive weeks. Skin measurement and self-assessment questionnaires will be conducted at baseline (before intake), after 1 week, and 4 weeks of consumption.
- Conditions
- Skin Condition, Collagen Synthesis
- Being tested
- Collagen Drink, MAXI Collagen Drink, MAXI Collagen Drink_High dose
- Keywords
- MAXI Collagen, Hydrolyzed collagen, Oral Collagen
- Medical subject headings
- Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collagen DrinkDietary supplement
consume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 5 g Collagen Powder
MAXI Collagen DrinkDietary supplement
consume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 15 mL MAXI Collagen Liquid (equivalent to 5 g of deep hydrolyzed collagen net weight)
MAXI Collagen Drink_High doseDietary supplement
consume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 30 mL MAXI Collagen Liquid (equivalent to 10 g of deep hydrolyzed collagen net weight)
| Study group | Role | What they receive |
|---|---|---|
| Collagen Drink | Active comparator | oral intake 5 g collagen daily Receives: Dietary Supplement: Collagen Drink |
| MAXI Collagen Drink | Experimental | oral intake 15 mL MAXI collagen daily (equivalent to 5 g of deep hydrolyzed collagen net weight) Receives: Dietary Supplement: MAXI Collagen Drink |
| MAXI Collagen Drink_High dose | Experimental | oral intake 30 mL MAXI collagen daily (equivalent to 10 g of deep hydrolyzed collagen net weight) Receives: Dietary Supplement: MAXI Collagen Drink_High dose |
What is being measured
The primary outcome is the main question the study is designed to answer.
The change of collagen fiber fluorescence intensity
SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to evaluate the density and quality of dermal collagen fibers.
Measured: Change from Baseline collagen intensity at 4 weeks
Secondary outcomes (17)
The change of skin elasticity
Cutometer® MPA580 (CK, Germany) was utilized to measure the gross elasticity of the skin using suction method.
Measured: Change from Baseline skin elasticity at 4 weeks
The change of skin firmness
Cutometer® MPA580 (CK, Germany) was utilized to measure skin firmness and the area under the suction curve.
Measured: Change from Baseline skin firmness at 4 weeks
The change of epidermal thickness
SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to measure the depth of the epidermal layer using optical imaging.
Measured: Change from Baseline epidermal thickness at 4 weeks
The change of cheek skin roughness
AEVA-HE (EOTECH, France) was utilized to measure the arithmetic average roughness (Ra value) of the cheek surface.
Measured: Change from Baseline skin roughness at 4 weeks
The change of the Dermal-Epidermal Junction (DEJ) structures
SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to assess the structural integrity and epithelial-connective tissue interface (ECTI) of the DEJ.
Measured: Change from Baseline DEJ status at 4 weeks
The change of nasolabial folds volume
AEVA-HE (EOTECH, France) was utilized to quantify the 3D morphological changes of the nasolabial folds volume.
Measured: Change from Baseline wrinkle parameters at 4 weeks
The change of nasolabial folds depth
AEVA-HE (EOTECH, France) was utilized to quantify the 3D morphological changes of the nasolabial folds depth.
Measured: Change from Baseline wrinkle parameters at 4 weeks
The change of crow's feet volume
AEVA-HE (EOTECH, France) was utilized to measure the severity of crow's feet volume.
Measured: Change from Baseline crow's feet parameters at 4 weeks
The change of crow's feet depth
AEVA-HE (EOTECH, France) was utilized to measure the severity of crow's feet depth.
Measured: Change from Baseline crow's feet parameters at 4 weeks
The change of the volume of fine lines under the eyes
AEVA-HE (EOTECH, France) was utilized to assess the volume of fine lines under the eyes.
Measured: Change from Baseline fine lines at 4 weeks
The change of the mean depth of fine lines under the eyes
AEVA-HE (EOTECH, France) was utilized to assess the mean depth of fine lines under the eyes.
Measured: Change from Baseline fine lines at 4 weeks
The change of cheek (malar) volume
AEVA-HE (EOTECH, France) was utilized to measure the 3D volume of the cheek area for lifting effects.
Measured: Change from Baseline cheek volume at 4 weeks
The change of jawline length
AEVA-HE (EOTECH, France) was utilized to measure the linear length and contour of the jawline.
Measured: Change from Baseline jawline parameters at 4 weeks
The change of skin pores counts
AEVA-HE (EOTECH, France) was utilized to perform 3D imaging and quantification of skin pores counts.
Measured: Change from Baseline pore parameters at 4 weeks
The change of skin pores volume
AEVA-HE (EOTECH, France) was utilized to perform 3D imaging and quantification of skin pores volume.
Measured: Change from Baseline pore parameters at 4 weeks
The change of skin hydration
Corneometer® CM825 (CK, Germany) was utilized to measure skin surface hydration. Units: arbitrary Corneometer® units 0-120.
Measured: Change from Baseline skin hydration at 4 weeks
The change of transepidermal water loss (TEWL)
Tewameter® TM300 (CK, Germany) was utilized to measure the evaporation rate of water from the skin. Units: g/h/m^2.
Measured: Change from Baseline TEWL at 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2026
- Study start12 May 2026
- Primary completion15 Jun 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 105 participants (actual)
Sponsor and investigators
- Lead sponsor
- TCI Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- YAO PAN, Principal investigator, Beijing Ewish Testing Technology Co.,ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07605871
- Sponsor's protocol ID
- SECCR2025-254
- Status last verified
- Jul 2026
- First submitted
- 8 May 2026
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Oral Collagen Drinks on Human Skin
- ClinicalTrials.gov ID
- NCT07605871
- Acronym / sponsor ID
- SECCR2025-254
- Conditions
- Skin Condition, Collagen Synthesis
- Keywords
- MAXI Collagen, Hydrolyzed collagen, Oral Collagen
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 105 participants (actual)
- Lead sponsor
- TCI Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 12 May 2026 (actual)
- Primary completion
- 15 Jun 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 26 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the effect of oral collagen drink and MAXI collagen drink on human skin condition improvement.
Detailed description
This study is a single-center, double-blinded, parallel human trial designed to evaluate the skin beauty effect of oral collagen drink and MAXI collagen drink.
Healthy adult participants aged 18-60 years will be enrolled. Participants will be informed to consume test samples daily for 4 consecutive weeks. Skin measurement and self-assessment questionnaires will be conducted at baseline (before intake), after 1 week, and 4 weeks of consumption.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Collagen Drink | Active comparator | Dietary Supplement: Collagen Drinkoral intake 5 g collagen daily |
| MAXI Collagen Drink | Experimental | Dietary Supplement: MAXI Collagen Drinkoral intake 15 mL MAXI collagen daily (equivalent to 5 g of deep hydrolyzed collagen net weight) |
| MAXI Collagen Drink_High dose | Experimental | Dietary Supplement: MAXI Collagen Drink_High doseoral intake 30 mL MAXI collagen daily (equivalent to 10 g of deep hydrolyzed collagen net weight) |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Healthy Chinese subjects aged 18 to 60 years, both male and female.
- Wrinkle Severity: Crow's feet graded 2-4; under-eye fine lines graded 2-5; nasolabial folds graded 1-3.
- Presence of facial skin laxity and sagging.
- Ability to undergo skin examinations and pre-treatment in the designated test areas.
- Ability to understand the trial process, participate voluntarily, and sign a written Informed Consent Form (ICF).
Key exclusion criteria (8 listed)
- Pregnant or lactating women, or those planning to become pregnant in the near future.
- Highly sensitive constitution, history of allergic diseases, or history of allergies to cosmetics.
- Presence of skin diseases (e.g., psoriasis, eczema, atopic dermatitis, severe acne) or other chronic systemic diseases.
- Skin conditions in the test area such as birthmarks, hyperpigmentation, inflammation, scars, nevi (moles), or hypertrichosis (excessive hair).
- Use of anti-inflammatory drugs (e.g., oral or topical corticosteroids) within the past month.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collagen Drinkconsume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 5 g Collagen Powder | Dietary supplement | Collagen Drink |
| MAXI Collagen Drinkconsume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 15 mL MAXI Collagen Liquid (equivalent to 5 g of deep hydrolyzed collagen net weight) | Dietary supplement | MAXI Collagen Drink |
| MAXI Collagen Drink_High doseconsume 1 bottle of the test samples daily for 4 consecutive weeks, each bottle containing 30 mL MAXI Collagen Liquid (equivalent to 10 g of deep hydrolyzed collagen net weight) | Dietary supplement | MAXI Collagen Drink_High dose |
Primary outcome
The change of collagen fiber fluorescence intensity
Time frame: Change from Baseline collagen intensity at 4 weeks
SUPERVISION-780 In-Vivo Imaging System (Survface, China) was utilized to evaluate the density and quality of dermal collagen fibers.
17 secondary outcomes
The change of skin elasticity
Time frame: Change from Baseline skin elasticity at 4 weeks
The change of skin firmness
Time frame: Change from Baseline skin firmness at 4 weeks
The change of epidermal thickness
Time frame: Change from Baseline epidermal thickness at 4 weeks
The change of cheek skin roughness
Time frame: Change from Baseline skin roughness at 4 weeks
The change of the Dermal-Epidermal Junction (DEJ) structures
Time frame: Change from Baseline DEJ status at 4 weeks
The change of nasolabial folds volume
Time frame: Change from Baseline wrinkle parameters at 4 weeks
The change of nasolabial folds depth
Time frame: Change from Baseline wrinkle parameters at 4 weeks
The change of crow's feet volume
Time frame: Change from Baseline crow's feet parameters at 4 weeks
The change of crow's feet depth
Time frame: Change from Baseline crow's feet parameters at 4 weeks
The change of the volume of fine lines under the eyes
Time frame: Change from Baseline fine lines at 4 weeks
The change of the mean depth of fine lines under the eyes
Time frame: Change from Baseline fine lines at 4 weeks
The change of cheek (malar) volume
Time frame: Change from Baseline cheek volume at 4 weeks
The change of jawline length
Time frame: Change from Baseline jawline parameters at 4 weeks
The change of skin pores counts
Time frame: Change from Baseline pore parameters at 4 weeks
The change of skin pores volume
Time frame: Change from Baseline pore parameters at 4 weeks
The change of skin hydration
Time frame: Change from Baseline skin hydration at 4 weeks
The change of transepidermal water loss (TEWL)
Time frame: Change from Baseline TEWL at 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
Related trials for Skin Condition
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
YAO PAN principal investigator
Beijing Ewish Testing Technology Co.,ltd.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Collagen Drink, MAXI Collagen Drink and MAXI Collagen Drink_High dose in people with Skin Condition and Collagen Synthesis, run by TCI Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The change of collagen fiber fluorescence intensity (time frame: Change from Baseline collagen intensity at 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.